PCR devices market seen reaching $9.84 billion by 2030

The market for PCR devices, reagents and uses is projected to grow from $6.97 billion in 2026 to $9.84 billion by 2030, driven by infectious disease testing, genomics research and personalized medicine. North America held the largest regional share in 2025, while real-time PCR and miniaturized instruments are emerging as key trends.

Why it matters: - PCR technology remains a core tool for rapid genetic analysis, infectious disease detection and biomedical research. - Rising demand for faster diagnostics and broader genetic screening is pushing adoption across clinical and research settings. - The market’s projected rise to $9.84 billion by 2030 signals continued investment in molecular diagnostics and lab infrastructure.

What happened: - The Business Research Company released a global market report on PCR devices, reagents and uses covering 2026-2035. - The report estimates the market will grow from $6.97 billion in 2026 to $9.84 billion by 2030. - The forecast implies a 9.0% compound annual growth rate through 2030. - The report says the market was $6.51 billion in 2025 and grew at a 7.2% CAGR into 2026. - North America held the largest regional share in 2025. - Western Europe ranked second by market size in 2025.

The details: - PCR devices and reagents are used to amplify specific DNA segments through repeated synthesis cycles. - The technique relies on short synthetic DNA pieces called primers to target a genome segment. - PCR is used in genetics, diagnostics and biomedical research. - Historical growth was driven by infectious disease outbreaks, genomics research, expansion of clinical diagnostic laboratories, COVID-19 testing demand and broader use of molecular biology methods. - Future growth is expected to come from personalized medicine, cancer diagnostics, genetic screening, research funding and demand for rapid diagnostic tools. - The report highlights growing demand for molecular diagnostics, expanded infectious disease testing, greater use of real-time PCR, more research-oriented PCR applications and smaller PCR instruments. - The report cites increased infectious disease prevalence as a major market driver. - In February 2024, the UK Health Security Agency reported a 10.7% rise in tuberculosis cases in England, to 4,850 in 2023 from 4,380 in 2022. - The report covers additional regions including Asia-Pacific, South East Asia, Eastern Europe, South America, the Middle East and Africa. - The 2026 report includes market attractiveness scoring, TAM analysis, a company scoring matrix, Excel-based forecasting dashboards, market hotspot infographics, and updated graphics and tables. - The report offers a free sample and full report through the company’s sample page and the full market report.

Between the lines: - The forecast points to a market moving from pandemic-era testing demand toward longer-term growth tied to routine diagnostics, cancer care and personalized medicine. - Real-time PCR and instrument miniaturization suggest buyers want faster workflows and more portable lab tools. - Regional leadership by North America suggests the largest installed base and research demand remain concentrated in mature health care markets.

What's next: - The market is expected to continue expanding through 2030 as more health systems adopt rapid molecular testing. - Ongoing funding for genomics and molecular biology research should support new PCR use cases. - PCR instrument makers may keep pushing smaller devices and automated workflows to meet demand for speed and scale.

The bottom line: - PCR remains a foundational diagnostics and research market, and the next growth phase is likely to be driven by everyday clinical use rather than emergency testing alone.